AnPac Bio-Medical Science Co., Ltd. (ANPC): Price and Financial Metrics
GET POWR RATINGS... FREE!
ANPC Stock Price Chart Interactive Chart >
ANPC Price/Volume Stats
| Current price | $9.78 | 52-week high | $18.67 |
| Prev. close | $9.31 | 52-week low | $2.60 |
| Day low | $8.96 | Volume | 16,700 |
| Day high | $9.79 | Avg. volume | 43,100 |
| 50-day MA | $5.62 | Dividend yield | N/A |
| 200-day MA | $5.16 | Market Cap | 9.48M |
AnPac Bio-Medical Science Co., Ltd. (ANPC) Company Bio
Anpac Bio-Medical Science Co., Ltd., a development-stage biotechnology company, researches, develops, markets, and sells multi-cancer screening and detection tests to corporations and life insurance companies in the People's Republic of China and the United States. It also manufactures cancer differentiation analysis devices; and offers physical checkup package services. The company was founded in 2010 and is headquartered in Lishui, the People's Republic of China.
Latest ANPC News From Around the Web
Below are the latest news stories about ANPAC BIO-MEDICAL SCIENCE CO LTD that investors may wish to consider to help them evaluate ANPC as an investment opportunity.
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on ThursdayIt's time to start the day with a breakdown of the biggest pre-market stock movers traders need to know about on Thursday! |
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on WednesdayIt's time for another look at the biggest pre-market stock movers worth checking out as we start off trading early on Wednesday! |
AnPac Bio-Medical Science Announces Signing of US$5.2 Million of Definitive Investment AgreementsNew York, NY, Jan. 25, 2023 (GLOBE NEWSWIRE) -- AnPac Bio-Medical Science Co., Ltd. (the “Company”) (Nasdaq: ANPC), a biotechnology company with operations in the United States and China focused on early cancer screening and detection and a business-to-business food e-commerce company, announced that in December 2022 and January 2023, the Company signed definitive investment agreements with several third party investors. The investors agreed to purchase 29,714,279 newly issued Class A ordinary s |
AnPac Bio-Medical Sciences Announces Receipt of Staff Delisting Determination from Nasdaq; Intends to Request A HearingNew York, NY, Jan. 20, 2023 (GLOBE NEWSWIRE) -- AnPac Bio-Medical Science Co., Ltd. (the “Company”) (Nasdaq: ANPC), a biotechnology company with operations in the United States and China focused on early cancer screening and detection announced that, on January 13, 2023, it received a Staff determination letter (the “Letter”) from the Listing Qualifications Department of The Nasdaq Stock Market LLC (“Nasdaq”) notifying the Company of the Staff’s determination to delist the Company’s securities f |
AnPac Bio Reports 48.8% Decrease in Net Loss in First Half of 2022PHILADELPHIA, Dec. 19, 2022 (GLOBE NEWSWIRE) -- AnPac Bio-Medical Science Co., Ltd. (“AnPac Bio,” the “Company” or “we”) (NASDAQ: ANPC), a biotechnology company with operations in China and the United States, announced today its unaudited financial results for the six months ended June 30, 2022. Financial highlights for the First Half of 2022 ● Total revenue was approximately RMB5.2 million (US$778,000) for the six months ended June 30, 2022, a decrease of 43.7% from approximately RMB9.3 million |
ANPC Price Returns
| 1-mo | 79.12% |
| 3-mo | 154.69% |
| 6-mo | 106.33% |
| 1-year | -41.08% |
| 3-year | -95.02% |
| 5-year | N/A |
| YTD | 108.97% |
| 2022 | -80.82% |
| 2021 | -76.98% |
| 2020 | N/A |
| 2019 | N/A |
| 2018 | N/A |
Loading social stream, please wait...